Human Genome Sciences, Inc.

ACTIVE

14200 Shady Grove Rd, Rockville, Maryland, United Stateswww.hgsi.comSubsidiary10,001+ employeesEstablished: 1992-01-01

Part of 葛兰素史克

Clinical Trials

39 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1992

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

38.2%

Phase 2

17.6%

Phase 3

11.8%

Not Applicable

7.3%

Trial Status Distribution

Active, not recruiting

54.4%

Completed

35.3%

Not yet recruiting

2.9%

Terminated

4.4%

Withdrawn

1.5%

Clinical Trials

Trials sponsored by this organization (68)

BREVAS

Not Applicable

Completed

interventional

Apr 201410 participants

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 52-WEEK STUDY TO ASSESS ADVERSE EVENTS OF SPECIAL INTEREST IN ADULTS WITH ACTIVE, AUTOANTIBODY-POSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS RECEIVING BELIMUMAB

Not Applicable

Completed

interventional

Feb 20144 participants

A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BELIMUMAB (HGS 1006) ADMINISTERED SUBCUTANEOUSLY (SC) TO SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE).

Not Applicable

interventional

Oct 2012

Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

Phase 1

Active, not recruiting

Oct 2012464 participants

A Study of Belimumab Administered Subcutaneously in Subjects with Systemic Lupus Erythematosus (SLE)

Active, not recruiting

Feb 2012816 participants

A Study of Belimumab Administered Subcutaneously in Subjects with Systemic Lupus Erythematosus (SLE)

Active, not recruiting

Jan 2012816 participants

Study to Evaluate the Pharmacodynamics and Safety of HGS1025 in Patients With Ulcerative Colitis

Study of Belimumab Administered Subcutaneously to Healthy Subjects

Phase 1

Completed

interventional

Feb 2011118 participants

Page 1 of 9

Approvals

No approval data available

News

No news articles found

Back to Organizations